Evidence map›Paper›PMID 26192190›Full record

ArticlePloS one2015

The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.

François M J Lamoury, Brendan Jacka, Sofia Bartlett, Rowena A Bull, Arthur Wong, Janaki Amin, Janke Schinkel, Art F Poon, Gail V Matthews, Jason Grebely and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

François M J LamouryThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Brendan JackaThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Sofia BartlettThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Rowena A BullInflammation and Infection Research Centre, School of Medical Sciences, University of New South Wales Australia, Sydney, Australia.
Arthur WongThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Janaki AminThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Janke SchinkelAcademic Medical Centre, Department of Medical Microbiology, Section of Clinical Virology, Amsterdam, The Netherlands.
Art F PoonBC Centre for Excellence in HIV/AIDS, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, Canada.
Gail V MatthewsThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Jason GrebelyThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Gregory J DoreThe Kirby Institute, University of New South Wales Australia, Sydney, Australia; HIV/Immunology/Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, Australia.
Tanya L ApplegateThe Kirby Institute, University of New South Wales Australia, Sydney, Australia.
UNSW Sydney · AUAmsterdam UMC Location University of Amsterdam · NLSt Vincent's Hospital Melbourne · AUUniversity of British Columbia · CA

Funding

Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
NIDA NIH HHS R01 DA015999
6 · The paper itself

Abstract

Sequencing is important for understanding the molecular epidemiology and viral evolution of hepatitis C virus (HCV) infection. To date, there is little standardisation among sequencing protocols, in-part due to the high genetic diversity that is observed within HCV. This study aimed to develop a novel, practical sequencing protocol that covered both conserved and variable regions of the viral genome and assess the influence of each subregion, sequence concatenation and unrelated reference sequences on phylogenetic clustering analysis. The Core to the hypervariable region 1 (HVR1) of envelope-2 (E2) and non-structural-5B (NS5B) regions of the HCV genome were amplified and sequenced from participants from the Australian Trial in Acute Hepatitis C (ATAHC), a prospective study of the natural history and treatment of recent HCV infection. Phylogenetic trees were constructed using a general time-reversible substitution model and sensitivity analyses were completed for every subregion. Pairwise distance, genetic distance and bootstrap support were computed to assess the impact of HCV region on clustering results as measured by the identification and percentage of participants falling within all clusters, cluster size, average patristic distance, and bootstrap value. The Robinson-Foulds metrics was also used to compare phylogenetic trees among the different HCV regions. Our results demonstrated that the genomic region of HCV analysed influenced phylogenetic tree topology and clustering results. The HCV Core region alone was not suitable for clustering analysis; NS5B concatenation, the inclusion of reference sequences and removal of HVR1 all influenced clustering outcome. The Core-E2 region, which represented the highest genetic diversity and longest sequence length in this study, provides an ideal method for clustering analysis to address a range of molecular epidemiological questions.

Indexed as

PhylogenyCluster AnalysisEvolution, MolecularGenotypeHepacivirusHumansRNA, ViralSequence Analysis, RNARNA, Viral

Identifiers

PMID26192190
PMCPMC4507989
OpenAlexW982677670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.